Pharvaris-funded real-world HAE management analysis flags treatment satisfaction gaps, published in Advances in Therapy

• Pharvaris reported publication of a funded real-world analysis on hereditary angioedema management in Advances in Therapy; results have already been presented in print.
• Findings flagged a gap between guideline-recommended care and routine practice, with treatment burden shaping satisfaction and switching decisions.
• Many patients did not treat every attack, often due to perceived low severity or practical barriers tied to injectable therapies.
• Patient feedback favored daily oral prevention over intermittent injections, pointing to continued unmet need for more usable options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050650PRIMZONEFULLFEED9838897) on October 05, 2026, and is solely responsible for the information contained therein.